Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Precise human epidermal growth factor receptor 2 (HER2) interpretation is crucial for breast cancer treatment selection. Evolving HER2 scoring challenges, especially for HER2-low cases, necessitate updated guidelines for accurate patient triage.
Area Of Science
- Oncology
- Pathology
- Biomarker Analysis
Background
- Human epidermal growth factor receptor 2 (HER2)-positive breast cancer treatment relies on targeted therapies.
- Accurate HER2 immunohistochemistry (IHC) is essential for patient selection for HER2-targeted treatments.
- The introduction of HER2-targeted antibody-drug conjugates for HER2-low breast cancers complicates IHC interpretation.
Purpose Of The Study
- To review the evolving challenges in HER2 IHC interpretation.
- To address the complexities introduced by HER2-low breast cancer classification.
- To provide practical recommendations for standardized HER2 IHC scoring.
Main Methods
- Literature review of current HER2 IHC methodologies.
- Analysis of interobserver and interlaboratory variability in HER2 scoring.
- Discussion of emerging diagnostic criteria for HER2-low status.
Main Results
- HER2 IHC interpretation faces challenges, particularly in distinguishing HER2-low cases (0-1+).
- Significant variability exists across different staining platforms and among pathologists.
- Current scoring systems may not adequately capture nuances for novel therapeutic eligibility.
Conclusions
- Standardized HER2 IHC interpretation is critical for effective patient stratification.
- Addressing variability in HER2 scoring is necessary to optimize treatment selection for both HER2-positive and HER2-low breast cancers.
- Updated guidelines and recommendations are needed to navigate the evolving landscape of HER2-targeted therapies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...